Back HIV/AIDS

HIV / AIDS

Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks

The Genvoya single-tablet regimen containing tenofovir alafenamide (TAF) suppressed HIV as well as a similar coformulation containing the older tenofovir disoproxil fumarate (TDF), but demonstrated better bone and kidney tolerability after 2 years of treatment, according to a report in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes.

alt

BHIVA 2016: Which Men Stand to Benefit Most from PrEP?

New data from the PROUD pre-exposure prophylaxis (PrEP) study have identified the characteristics of the gay and other men who have sex with men who are most likely to benefit from PrEP, according to findings reported at the recent conference of the British HIV Association (BHIVA) in Manchester. Gay men with rectal sexually transmitted infections (STIs) and those who had unprotected receptive anal sex with more partners were most likely to benefit from PrEP.

alt

Opt-Out HIV, HBV, and HCV Testing in Emergency Departments Identifies Many New Infections

A week-long pilot study involving 9 U.K. emergency departments has shown that routine opt-out testing for HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) can identify a significant number of previously undiagnosed infections, according to study results published in the March edition of HIV Medicine.

alt

Positively Trans Survey Looks at Lives of Transgender People Living with HIV

The Transgender Law Center (TLC) released in March the first report of findings from its Positively Trans survey, which aims to learn more about the lives and experiences of transgender people living with HIV.TLC, working with a national advisory board of trans community leaders and with support from the Elton John AIDS Foundation, launched the survey in response to the structural inequities that drive the high rate of HIV/AIDS and poor health outcomes among trans people.

alt

CROI 2016: Studies Probe Retention in Care for HIV+ Women Who Start ART During Pregnancy

Engaging lay counselors to provide a combination package of evidence-based interventions in Nyanza, Kenya, and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ program improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) show.

alt

California Demonstration Projects to Study HIV PrEP for Transgender People

The California HIV/AIDS Research Program has announced funding for 3 new pre-exposure prophylaxis (PrEP) demonstration projects that will explore the use of Truvada (tenofovir/emtricitabine) for HIV prevention for transgender women and men, with a focus on improving adherence and monitoring interactions between antiretrovirals and gender-affirming hormone therapy.

alt

Gene Therapy Snips HIV Out of Infected Cells and Makes Uninfected Cells Resistant

For the first time, researchers have used a gene-editing technique related to one already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed to remove HIV genes completely from infected cells, as shown by reductions in the cells' overall rate of HIV production. In cells not already infected, the therapy has itself become part of their genome, producing cells that are resistant to infection for a prolonged period, according to a report in a recent edition of Nature Scientific Reports.

alt